The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors.
 
Sanjay Goel
Stock and Other Ownership Interests - Johnson and Johnson; Merck; Moderna Therapeutics
Honoraria - Amgen; Merck
Research Funding - BeiGene (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); PharmaMar (Inst); Takeda (Inst); TLC PharmaChem (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - Array BioPharma; Bayer; Eisai; Incyte; Syros Pharmaceuticals
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Merck; Pfizer; Sanofi; Takeda
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Gan & Lee (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Immunocore (Inst); Intensity Therapeutics (Inst); Iovance Biotherapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Navire (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Seagen (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sumitomo Group (Inst); Takeda (Inst); Targovax (Inst)
(OPTIONAL) Uncompensated Relationships - Takeda
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; BAKX Therapeutics; Bayer; Black Diamond Therapeutics; Compass Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImCheck therapeutics; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Mekanistic Therapeutics; Molecular Templates; Molecular Templates; Pfizer; QED Therapeutics; Relay Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Seagen; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Stemline Therapeutics; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Rachel E. Sanborn
Honoraria - Amgen; AstraZeneca
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech/Roche; Janssen Oncology; Macrogenics; Mirati Therapeutics; Regeneron; Sanofi/Aventis
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck
Travel, Accommodations, Expenses - AstraZeneca
 
Sunil Sharma
Stock and Other Ownership Interests - Barricade Therapeutics; Beta Cat Pharmaceuticals; ConverGene; Elevar Therapeutics; HLB; Salarius Pharmaceuticals; Stingray Therapeutics
Honoraria - Array BioPharma
Consulting or Advisory Role - Barricade Therapeutics; Barricade Therapeutics; Barricade Therapeutics; Celularity; Dracen; Elevar Therapeutics; Elevar Therapeutics; Elevar Therapeutics
Research Funding - AADi; Amal Therapeutics; Celgene; Dracen; Honor Health; Honor Health; Inhibrx; Merck; Nektar; Novartis; Plexxikon; Sirnaomics; Syndax; Takeda; Tesaro; Toray Industries; Zai Lab
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Cancer. Provisional Application Serial No. 63/270,005.; Compositions and Methods for the Treatment of Coronavirus Infection. Provisional Application Serial No.: 63/005,780. Filing Date: 4/6/2020. TGen Ref No: 200401- 299PROV.; Imidazolopyrazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,954. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV2. Seed Ref. No.: 910255.403P1.; Imidazolopyridazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,951. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV1. Seed Ref. No.: 910255.402P1.; Imidazolotriazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,955. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV3. Seed Ref. No.: 910255.404P1.; Imidazopyridazine and Imidazopyrazine Compounds and Methods of Use Thereof. International PCT Patent Application No.: PCT/US2021/050936.; International PCT Application No. PCT/US20/13618 Title: BISPHOSPHONATE CONJUGATES AND USES THEREOF; Methods and Compounds for Neoantigen Vaccines Provisional Application Serial No.: 63/166,697.; Neoantigen-Informed Tumor-Infiltrating Lymphocyte Cancer Immunotherapy. WO 2021/222855. PCT/US2021/030331; Peptide Inhibitors Targeting the TBL1-Beta-Catenin Complex. Provisional Application Serial No.: 63/159,882; Provisional Application No. 62/961,930. Title: PepSeq as a platform to identify synthetic molecular binding agents; Provisional application number: 62/818,037 Title: Trisubstituted Pyrazolo [1, 5-a] Pyrimidine Compounds and Methods of Use Thereof
 
Leisha A. Emens
Leadership - Society for Immunotherapy of Cancer; Society for Immunotherapy of Cancer
Stock and Other Ownership Interests - Molecuvax
Consulting or Advisory Role - Abbvie; Bristol Meyers Squibb; Chugai Pharma; CytomX Therapeutics; DNAMx; Genentech/Roche; Gilead Sciences; GPCR Therapeutics; Immune-Onc Therapeutics; Immunitas; Lilly; Macrogenics; Molecuvax; Replimune; Shionogi; Silverback Therapeutics
Research Funding - Abbvie; Aduro Biotech; AstraZeneca; Bolt Biotherapeutics; Bristol Myers Squibb; Compugen; Corvus Pharmaceuticals; CytomX Therapeutics; EMD Serono; Genentech; Immune-Onc Therapeutics; Maxcyte; Merck; NextCure; Roche; Silverback Therapeutics; Takeda; Tempest Therapeutics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Roche
Other Relationship - Aduro Biotech
 
Matthew Reilley
Stock and Other Ownership Interests - Molecular Templates
Honoraria - BMS; Natera
 
Victor Priego
No Relationships to Disclose
 
Shuli Li
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Bingxia Wang
Employment - Takeda
 
Lixian Dong
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Kris Sachsenmeier
Employment - Takeda
Leadership - Takeda
Stock and Other Ownership Interests - AstraZeneca; PLC Health Solutions
Patents, Royalties, Other Intellectual Property - AstraZeneca; PLC Health Solutions
Travel, Accommodations, Expenses - AstraZeneca; PLC Health Solutions; Takeda
(OPTIONAL) Uncompensated Relationships - BreakBio Corp.
 
John Gibbs
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Robert Gharavi
Employment - Takeda
 
Alonzo Martinez
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Igor Proscurshim
Employment - Ichnos Sciences; Takeda
Stock and Other Ownership Interests - Ichnos Sciences; Takeda
Patents, Royalties, Other Intellectual Property - Agenus; Takeda
 
Robert J. Fram
Employment - Takeda
Stock and Other Ownership Interests - Baxter; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson; Pfizer; Takeda; Viatris; Zimmer Biomet
Consulting or Advisory Role - BeyondSpring Pharmaceuticals
Travel, Accommodations, Expenses - Takeda
 
Alejandro Gomez-Pinillos
Employment - Takeda
 
Drew W. Rasco
Research Funding - 23andMe (Inst); Abbvie (Inst); Arcus Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Cullinan Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Kronos; Merck (Inst); Molecular Templates; PureTech (Inst); Seven and Eight Biopharmaceuticals (Inst); Surface Oncology (Inst); Takeda (Inst); TD2 (Inst)